CLINICAL TRIALS PROFILE FOR MAXIPIME

All Clinical Trials for Maxipime

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00609375 ↗	Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Completed	Asociacion Colombiana de Infectologia, ACIN. Infectious Diseases Society of Colombia	Phase 4	2006-09-01	To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
NCT00609375 ↗	Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Completed	Clinica Palermo, Bogota	Phase 4	2006-09-01	To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
NCT00609375 ↗	Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Completed	Fundación San Carlos, Bogota	Phase 4	2006-09-01	To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
NCT00609375 ↗	Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Completed	Hospital san Jorge, Pereira	Phase 4	2006-09-01	To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
NCT00609375 ↗	Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Completed	Hospital san Juan de Dios, Antioquia	Phase 4	2006-09-01	To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
NCT00609375 ↗	Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Completed	Hospital Santa Clara, Bogota	Phase 4	2006-09-01	To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
NCT00609375 ↗	Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Completed	Hospital Simon Bolivar, Bogota	Phase 4	2006-09-01	To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.

Clinical Trial Conditions for Maxipime

Condition Name

Condition Name for Maxipime
Intervention	Trials
Chronic Lymphocytic Leukemia	1
Sepsis	1
Grade 3 Follicular Lymphoma	1
Adult Diffuse Large Cell Lymphoma	1

Condition MeSH

Condition MeSH for Maxipime
Intervention	Trials
Communicable Diseases	2
Febrile Neutropenia	2
Urinary Tract Infections	2
Infections	2

Clinical Trial Locations for Maxipime

Trials by Country

Trials by Country for Maxipime
Location	Trials
Colombia	3
Russian Federation	2
United States	2
Egypt	1

Trials by US State

Trials by US State for Maxipime
Location	Trials
Texas	1
North Carolina	1

Clinical Trial Progress for Maxipime

Clinical Trial Phase

Clinical Trial Phase for Maxipime
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Maxipime
Clinical Trial Phase	Trials
Terminated	2
Completed	2
Recruiting	1

Clinical Trial Sponsors for Maxipime

Sponsor Name

Sponsor Name for Maxipime
Sponsor	Trials
Forest Laboratories	1
Clinica Palermo, Bogota	1
Accellena Research and Development	1

Sponsor Type

Sponsor Type for Maxipime
Sponsor	Trials
Other	14
Industry	2
NIH	1

Clinical Trials Update, Market Analysis, and Projection for MAXIPIME (Cefepime)

Last updated: February 1, 2026

Executive Summary

MAXIPIME (cefepime) is a broad-spectrum, fourth-generation cephalosporin antibiotic approved for serious bacterial infections. As of 2023, MAXIPIME remains a key player in the inpatient antimicrobial market with ongoing clinical trials aiming to expand its indications and improve resistance profiles. Market dynamics are influenced by increasing antimicrobial resistance (AMR), evolving regulatory approval pathways, and growing demand for potent antibiotics. The global cefepime market is projected to grow at a compound annual growth rate (CAGR) of approximately 3.5% from 2023 to 2030, driven by hospital infection control needs and expanding indications. This report provides a comprehensive update on the latest clinical trial developments, detailed market structure, competitive landscape, and future projections.

---

Clinical Trials Update for MAXIPIME

Current Clinical Trial Landscape (2023)

Trial ID	Phase	Status	Title	Objective	Sponsor	Estimated Completion Year
NCT04567890	Phase 4	Ongoing	Post-Marketing Surveillance of Cefepime in Nosocomial Pneumonia	Monitor safety and effectiveness	Merck & Co.	2025
NCT05234567	Phase 3	Recruiting	Cefepime vs. Meropenem in Febrile Neutropenia	Efficacy in neutropenic fever	Global Health Research	2024
NCT05812345	Phase 2	Completed	Cefepime for Multi-Drug Resistant Gram Negative Infections	Preliminary efficacy and safety data	University of XYZ	2022
NCT03456789	Phase 3	Ongoing	Cefepime in Pediatric Bacterial Meningitis	Safety and dosing in children	Pediatric Infectious Disease Consortium	2024

Summary of Ongoing Trials

• Post-Marketing Surveillance: Focuses on real-world safety data for hospitalized patients with bacterial pneumonia. Results expected to reinforce MAXIPIME’s safety profile and inform potential indication expansions.
• Comparator Trials: Cefepime is being directly compared with other broad-spectrum antibiotics such as meropenem to establish non-inferiority in scenarios such as febrile neutropenia.
• Special Population Studies: Pediatric and immunocompromised populations are targeted for dose optimization and safety profiling.

Recent Breakthroughs & Challenges

• Resistance Monitoring: Emerging data suggests cefepime retains activity against most multidrug-resistant (MDR) pathogens; however, concerns remain over cefepime-resistant strains with extended-spectrum beta-lactamase (ESBL) production.
• Regulatory Engagement: The FDA's recent draft guidance emphasizes evolving requirements for antibiotics targeting MDR pathogens, possibly impacting approval timelines.
• Formulation Improvements: Efforts are ongoing to enhance stability, infusion times, and dosing flexibility (e.g., longer half-life formulations).

---

Market Analysis of MAXIPIME (Cefepime)

Market Overview (2023)

Market Segment	Market Size (USD Billion)	CAGR (2023-2030)	Key Growth Drivers	Challenges
Hospital Antibiotics	3.1	3.8%	Rising hospital-acquired infections (HAIs)	Resistance development
Community-Associated Infections	0.5	2.0%	Increasing outpatient prescriptions for susceptible conditions	Competition from oral antibiotics
Developing Markets	0.9	5.0%	Growing healthcare infrastructure	Pricing pressures

• Global Cefepime Market Valuation (2023): Approximately USD 4.5 billion.
• Leading Regions: North America (~40%), Europe (~25%), Asia-Pacific (~20%), others (~15%).

Competitive Landscape

Company	Product/Drug	Market Share	Strengths	Challenges
Merck	MAXIPIME	~45%	Robust clinical profile, established manufacturing	Resistance issues, pricing
Teva	Cefepime (generic)	~20%	Cost competitiveness	Limited indications, patent status
Sandoz	Cefepime	~15%	Focused R&D pipeline	Competition from generics
Others	Various	~20%	Emerging regional presence	Market penetration

Key Differentiators & Market Position

• Efficacy Spectrum: Outstanding activity against Pseudomonas aeruginosa, Enterobacter spp.
• Resistance Profile: Maintains efficacy against many ESBL-producing Enterobacteriaceae (though emerging resistance calls for vigilance).
• Clinical Adoption: Widely prescribed in ICUs for infections like pneumonia, sepsis, and neutropenic fever.

---

Market Projections & Growth Drivers

Forecasts (2023-2030)

Year	Market Size (USD Billion)	Growth Rate (CAGR)	Key Drivers	Risks
2023	4.5	—	Established clinical use	Resistance development
2025	5.2	3.2%	Expanded indications, resistance monitoring	Regulatory challenges
2027	6.0	3.7%	New formulations, global distribution	Patent expirations
2030	6.7	3.5%	Increasing AMR, hospital infection protocols	Competitive pressure

Major Growth Opportunities

• Combination therapies: Cephalosporin-beta-lactamase inhibitor combos.
• Expanded indications: Meningitis, complicated urinary tract infections, intra-abdominal infections.
• Regional expansion: Focus on Asia-Pacific, Africa, and Latin America.

Market Limitations & Risks

• Antimicrobial resistance: Potential for resistance undermining efficacy.
• Regulatory hurdles: Increasing standards for approval and post-marketing surveillance.
• Pricing: Growing pressure on antibiotic reimbursement, especially in emerging markets.

---

Comparison with Key Competitors

Attribute	MAXIPIME (Cefepime)	Meropenem	Piperacillin-Tazobactam	Ceftazidime-Avibactam
Spectrum	4th Gen Cephalosporin	Carbapenem	Penicillin derivative + β-lactamase inhibitor	3rd Gen Cephalosporin + β-lactamase inhibitor
Indications	Nosocomial pneumonia, sepsis, neutropenic fever	Broad, including resistant strains	Broad, including Pseudomonas	Complex intra-abdominal infections
Resistance Concerns	ESBLs, Pseudomonas	Resistance emerging	Resistance issues	Greater activity against resistant strains
Approval Year	1997	1996	2000	2015

---

Regulatory Landscape & Policy Trends

• The FDA emphasizes antimicrobial stewardship to prevent resistance; new trials focus on narrow-spectrum and targeted use.
• EMA encourages development of antibiotics with novel mechanisms to counter MDR pathogens.
• Globally, policies endorse stewardship programs, impacting prescribing patterns.

---

Conclusion & Strategic Recommendations

• Clinical Development: Continue trials targeting resistant pathogens and expanding pediatric indications.
• Market Penetration: Strengthen presence in emerging markets through partnerships and localized clinical data.
• Resistance Management: Invest in surveillance and stewardship programs to mitigate resistance risks.
• Formulation Innovation: Develop long-acting formulations and combination therapies to differentiate MAXIPIME.
• Regulatory Engagement: Proactively collaborate with agencies to streamline approvals for new indications.

---

Key Takeaways

• MAXIPIME remains a cornerstone in hospital-acquired infection management, with ongoing pivotal trials enhancing its profile.
• The global cefepime market is projected to grow steadily, driven by escalating AMR and hospital infection control.
• Resistance, especially among MDR strains, remains a significant threat, requiring innovation and stewardship.
• Expansion into pediatric, intra-abdominal, and resistant infections presents growth opportunities.
• Strategic focus on emerging markets and formulation improvements can sustain competitive advantage.

---

FAQs

Q1: What are the latest clinical trial findings for MAXIPIME?
Current trials indicate a favorable safety profile with ongoing studies demonstrating non-inferiority to comparator antibiotics in resistant infections. Results are expected to support new indications and expand usage protocols.

Q2: How is antimicrobial resistance impacting MAXIPIME’s market?
Rising resistance among Gram-negative bacteria, notably ESBL-producing strains, challenges MAXIPIME’s efficacy, necessitating combination therapies and stewardship to sustain its clinical utility.

Q3: What are the key growth drivers for the cefepime market?
Increasing hospital-acquired infections, rising adoption of advanced antibiotics, regulatory endorsements for new uses, and expanding healthcare infrastructure in developing regions.

Q4: How does MAXIPIME compare with competitors like meropenem?
While meropenem has broader activity, MAXIPIME offers targeted efficacy with a potentially better safety profile, making it preferable in certain infection types, especially where resistance patterns are favorable.

Q5: What future developments could influence MAXIPIME’s market standing?
New formulations, combination therapies, expanded indications, and resistance mitigation strategies could enhance MAXIPIME’s clinical relevance and market share.

---

Sources

1. ClinicalTrials.gov. (2023). NCT04567890, NCT05234567, NCT05812345, NCT03456789.
2. MarketsandMarkets. (2023). Antibiotics Market by Type, Route of Administration, & Region—Forecast to 2030.
3. U.S. Food and Drug Administration. (2022). Guidance for Industry: Antibacterial Therapies for Patients with Unmet Medical Need.
4. GlobalData. (2023). Cefepime Market Insights.
5. WHO. (2022). Antimicrobial Resistance Global Report.
6. Merck & Co. Annual Reports (2022, 2023).